Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of 12.93% is 36% above its 5-year average of 9.49%, near the high end of its 5-year range (-35.51%–19.77%).
4.26% below its 12-month average of 13.51%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 18.33%.
OPERATING MARGIN
12.93%
OPERATING MARGIN AVG TTM
13.51%
OPERATING MARGIN AVG 3Y
14.42%
OPERATING MARGIN AVG 5Y
9.49%
OPERATING MARGIN AVG 10Y
10.72%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.26%
CURRENT VS 3Y AVG
-10.31%
CURRENT VS 5Y AVG
+36.29%
CURRENT VS 10Y AVG
+20.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Amneal Pharmaceuticals, Inc.
Market Cap
$6.50B
Operating Margin
12.93%
TTM Avg
13.51%
3Y Avg
14.42%
5Y Avg
9.49%
Market Cap
$6.61B
Operating Margin
-362.95%
TTM Avg
-1052.99%
3Y Avg
-3382.94%
5Y Avg
-3698.56%
Market Cap
$6.62B
Operating Margin
4.50%
TTM Avg
4.35%
3Y Avg
-1.93%
5Y Avg
-10.04%
Market Cap
$6.32B
Operating Margin
-153.08%
TTM Avg
-197.00%
3Y Avg
-9782.25%
5Y Avg
-6521.50%
Market Cap
$6.68B
Operating Margin
13.46%
TTM Avg
14.22%
3Y Avg
14.89%
5Y Avg
15.72%
Market Cap
$6.06B
Operating Margin
-4722.13%
TTM Avg
-7394.69%
3Y Avg
-15105.91%
5Y Avg
-12109.07%
Market Cap
$5.82B
Operating Margin
11.92%
TTM Avg
0.31%
3Y Avg
-1.06%
5Y Avg
-68.44%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.50B | 12.93% | 13.51% | 14.42% | 9.49% |
| GRAIL Inc. (GRAL)vs › | $6.61B | -362.95% | -1052.99% | -3382.94% | -3698.56% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.62B | 4.50% | 4.35% | -1.93% | -10.04% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.32B | -153.08% | -197.00% | -9782.25% | -6521.50% |
| Chemed Corporation (CHE)vs › | $6.68B | 13.46% | 14.22% | 14.89% | 15.72% |
| Immunovant, Inc. (IMVT)vs › | $6.86B | 0.00% | 0.00% | 0.00% | 0.00% |
| CG Oncology Inc. (CGON)vs › | $6.06B | -4722.13% | -7394.69% | -15105.91% | -12109.07% |
| Alkermes plc (ALKS)vs › | $7.17B | 17.21% | 22.11% | 17.14% | 11.01% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.82B | 11.92% | 0.31% | -1.06% | -68.44% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.23B | -40.47% | -53.92% | -55.65% | -41.65% |
Gross Margin
39.3%
Operating Margin
12.9%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 18.33% |
| 2026-03-31 | 19.77% |
| 2025-12-31 | 14.06% |
| 2025-09-30 | -0.01% |
| 2025-06-30 | 15.37% |
| 2025-03-31 | 14.43% |
| 2024-12-31 | 10.38% |
| 2024-09-30 | 12.64% |
| 2024-06-30 | 13.60% |
| 2024-03-31 | -1.63% |
| 2023-12-31 | 2.30% |
| 2023-09-30 | 12.20% |
| 2023-06-30 | 13.37% |
| 2023-03-31 | 6.18% |
| 2022-12-31 | 5.91% |
| 2022-09-30 | 8.13% |
| 2022-06-30 | -35.51% |
| 2022-03-31 | 4.68% |
| 2021-12-31 | 2.08% |
| 2021-09-30 | 5.39% |
| 2021-06-30 | 12.54% |
| 2021-03-31 | 9.31% |
| 2020-12-31 | 3.96% |
| 2020-09-30 | 0.47% |
| 2020-06-30 | 2.31% |
| 2020-03-31 | 11.59% |
| 2019-12-31 | -5.82% |
| 2019-09-30 | -29.68% |
| 2019-06-30 | -4.67% |
| 2019-03-31 | -21.15% |
| 2018-12-31 | 4.68% |
| 2018-09-30 | 15.65% |
| 2018-06-30 | -43.76% |
| 2018-03-31 | 23.09% |
| 2017-12-31 | 26.94% |
| 2017-09-30 | 30.92% |
| 2017-06-30 | 17.16% |
| 2017-03-31 | 18.93% |
| 2016-12-31 | 30.91% |
